

CONTINUING EDUCATION (CE) INFORMATION

CONFERENCE GOALS AND TARGET AUDIENCE

The ASPEN Nutrition Science & Practice Conference is designed for dietitians, nurses, physicians, pharmacists, researchers, and others who practice the sciences of clinical nutrition and metabolism. The conference provides nutrition support professionals with current and cutting-edge information in the field of nutrition support, clinical nutrition, and metabolism.

CONFERENCE OBJECTIVES

Upon conclusion of the conference, attendees will be able to:

- Challenge current clinical practices
- Integrate evidence-based updates into practice
- Reflect on the implications of current research
- Identify gaps in knowledge that require further education and training

LEARNING LEVELS

To assist in selecting sessions that are most appropriate for you, each session will be identified by learning level on the ASPEN website

at www.nutritioncare.org/conference:

BASIC: Assumes little or no prior knowledge of areas covered. The basic session is aimed toward individuals building a foundation for competent practice. This correlates to CDR level 1.

INTERMEDIATE: Assumes a general knowledge of the literature and clinical practice within the areas covered. Intermediate sessions are aimed toward individuals wishing to expand their skills and knowledge base. This correlates to CDR level 2.

ADVANCED: Assumes thorough knowledge of the literature and clinical practice within the areas covered. Advanced sessions are aimed toward individuals seeking a synthesis of recent advances and future directions. This correlates to CDR level 3.

VIRTUAL CONFERENCE

ASPEN21 is a virtual online conference presented live and in real-time to virtual attendees. Virtual attendees can ask questions and interact with speakers and faculty. Participants in the virtual conference must follow all processes for successful completion and all accreditation

guidelines apply.

SUCCESSFUL COMPLETION

ASPEN provides CE credit to physicians, nurses, pharmacists, and dietitians who attend in full each live session claimed for credit and complete the program evaluation process within the electronic CE system in ASPEN's eLearning Center, www.nutritioncare.org/elearning. Registered conference participants will need to login using their ASPEN credentials to gain access to the conference evaluations in the eLearning Center. *Of note, the live broadcast of the session is what is accredited, registered conference participants must log in and participate in the live broadcast to be eligible to claim credit.*

INTERNATIONAL PARTICIPANTS

Participant feedback is essential in the continued improvement of ASPEN's educational programs, including the annual conference. International participants are encouraged to use the electronic system to submit evaluations for the sessions attended and the overall conference. Through the electronic system, detailed documentation

Baxter

Clinolipid

[LIPID INJECTABLE EMULSION],
FOR INTRAVENOUS USE

RICH IN IMMUNE NEUTRAL OMEGA 9 FATTY ACIDS^{1,2}



Discover Clinolipid [HERE](#)

Brief Summary of Prescribing Information

See Package Insert for Full Prescribing Information

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use CLINOLIPID safely and effectively. See full prescribing information for CLINOLIPID.

CLINOLIPID (lipid injectable emulsion), for intravenous use
Initial U.S. Approval: 1975

WARNING: DEATH IN PRETERM INFANTS

- Deaths in preterm infants after infusion of intravenous lipid emulsions have been reported in the medical literature.
- Autopsy findings included intravascular fat accumulation in the lungs.
- Preterm and low birth weight infants have poor clearance of intravenous lipid emulsion and increased free fatty acid plasma levels following lipid emulsion infusion.

INDICATIONS AND USAGE

CLINOLIPID is indicated in adults for parenteral nutrition providing a source of calories and essential fatty acids when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Limitations of Use:

- CLINOLIPID is not indicated for use in pediatric patients because there is insufficient data to demonstrate that CLINOLIPID provides sufficient amounts of essential fatty acids in this population
- The omega-3: omega-6 fatty acid ratio in CLINOLIPID has not been shown to improve clinical outcomes compared to other intravenous lipid emulsions

DOSAGE AND ADMINISTRATION

- Use a 1.2 micron in-line filter when administering to a patient
- See full prescribing information for administration and admixing instructions
- CLINOLIPID is intended for intravenous infusion.
- The recommended dose depends on energy expenditure, clinical status, body weight, tolerance, ability to metabolize and consideration of additional energy given to patient. The usual daily lipid dosage in adults is 1 to 1.5 g/kg/day and should not exceed 2.5 g/kg/day.

DOSAGE FORMS AND STRENGTHS

CLINOLIPID 20% is a lipid injectable emulsion. The lipid content is 0.2 grams/mL in 100 mL, 250 mL, 500 mL, and 1000 mL.

CONTRAINDICATIONS

- Known hypersensitivity to egg and soybean proteins, the lipid emulsion and/or excipients.
- Severe hyperlipidemia or severe disorders of lipid metabolism.

WARNINGS AND PRECAUTIONS

- Preterm infants have poor clearance of intravenous lipid emulsion.
- Monitor for signs or symptoms of hypersensitivity reactions.
- Monitor for signs and symptoms of infection, fat overload, hypertriglyceridemia and refeeding complications.
- Frequent clinical and laboratory determinations are necessary.
- The aluminum contained in CLINOLIPID may reach toxic levels with prolonged administration in patients with impaired kidney function.
- Parenteral Nutrition Associated Liver Disease (PNALD) has been reported in patients who receive parenteral nutrition for extended periods of time, especially preterm infants.

ADVERSE REACTIONS

The most common (5%) adverse drug reactions from clinical trials were nausea and vomiting, hyperlipidemia, hyperglycemia, hypoproteinemia and abnormal liver function tests.

To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare at 1-866-888-2472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

DRUG INTERACTIONS

The anticoagulant activity of coumarin derivatives, including warfarin, may be counteracted.

USE IN SPECIFIC POPULATIONS

Hepatic Impaired: Use with caution in patients with preexisting liver disease or liver insufficiency.

Please visit www.baxterpi.com for Full Prescribing Information

[Click here](#) for full prescribing information.

1. Clinolipid [Lipid Injectable Emulsion, USP] 20% for intravenous use PI, 2016.
2. Vanek, et al. Nutr Clin Prac 2012;27:150-192.

CONTINUING EDUCATION (CE) INFORMATION

of the sessions attended at the conference will be provided on a discipline-specific transcript.

SYSTEM REQUIREMENTS FOR VIRTUAL CONFERENCE:

- Adobe Flash Plugin
- Internet Explorer 8+, Mozilla Firefox, Google Chrome, Safari
- Broadband Internet connection

*Also compatible with iOS and Android-based tablets and smartphones.

ACCREDITATION

NURSES, PHARMACISTS, AND PHYSICIANS



In support of improving patient care, The American Society for Parenteral and Enteral Nutrition (ASPEN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

A maximum of 19 contact hours/1.9 CEUs may be earned for the ASPEN 2021 Nutrition Science & Practice Conference.

UANs are provided with each session description online at nutritioncare.org/conference2021. Sessions not displaying UANs are unavailable for pharmacy credit.

ASPEN is approved by the California Board of Registered Nursing, provider number CEP 3970.

PRE-CONFERENCE (03/19/2021 -

03/20/2021): ASPEN designates this live activity for a maximum of 8.0 *AMA PRA Category 1 Credits*™.

MAIN CONFERENCE (03/20/2021 -

03/23/2021): ASPEN designates this live activity for a maximum of 19 *AMA PRA Category 1 Credits*™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DIETITIANS



ASPEN Provider AM005 is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will

receive a maximum of 8.0 continuing professional education units (CPEUs) for pre-conference program/materials, a maximum of 19 CPEUs for main conference program. CDR program levels are equivalent to the “basic,” “intermediate,” or “advanced” difficulty indicators found with session details at www.nutritioncare.org/conference. Dietitians may post comments on this program at QualityCPE@eatright.org.

VIRTUAL PRE-CONFERENCE PROGRAMMING

Pre-conference programming on March 19 – 20, 2021 provides a maximum of 8 continuing education hours. Programs include: Physician Pre-conference Course: Comprehensive Nutritional Therapy – Tactical Approaches in 2021 (8), Nutrition Support Fundamentals Course (8), Parenteral Nutrition Order Writing Workshop (8), Nutrition for the Practicing Pediatric Clinician (4), Research Workshop: Novel Nutritional Biomarkers (4), Post Graduate Course: Select GI States and Nutritional Implications (4).

VIRTUAL MAIN CONFERENCE PROGRAMMING

	MAX HRS.
March 20, 2021	1.0
March 21, 2021	5.5
March 22, 2021	7.0
March 23, 2021	5.5
Max for Virtual Conference*	19.0

Any additional credit for section forums will be noted in the final program materials.

NOTICES

- Ancillary/satellite programs and corporate symposia are not provided by ASPEN for continuing education credit.
- Faculty and planner disclosures and resolution of conflicts, if any, will be available in the conference disclosure supplement on the conference website prior to the conference: www.nutritioncare.org/conference.
- Information regarding discussion of the off-label use of products, if any, will be available in the conference disclosure supplement on the conference website prior to the conference: www.nutritioncare.org/conference.
- Detailed sponsorship and commercial support information will be included on the conference website prior to the conference www.nutritioncare.org/conference.
- ASPEN subscribes to the ACCME Standards for

Commercial Support.

- ASPEN does not provide programs that constitute advertisement or include promotional content.
- ASPEN does not endorse any products.

PRIVACY

ASPEN respects the privacy of its members and website visitors. Companies that receive personal information from ASPEN in order to execute the business of ASPEN may use personal information only for that purpose.

GRIEVANCES

Should be addressed in writing to:

ASPEN
Director, Education and Research
8401 Colesville Road, Suite 510
Silver Spring, MD 20910

AMERICANS WITH DISABILITIES ACT AND SPECIAL SERVICES

ASPEN takes steps to provide reasonable accommodation to ensure that no individual who is physically challenged is excluded, denied services, segregated, or otherwise treated differently because of an absence of auxiliary aids and services identified in the Americans with Disabilities Act. If you require special services, please contact ASPEN at aspen@nutritioncare.org.

DEFINITIONS

Contributed by: signifies that an organization outside ASPEN has contributed content for the session. For example: “Contributed by the Canadian Nutrition Society (CNS)”. All sessions contributed by other organizations were reviewed and approved by the ASPEN Conference Program Committee.

Presented by: signifies that a chapter or section within ASPEN is presenting the session. For example: “Presented by the ASPEN Ibero Latin American Section (ILAS)”. All sessions presented by an ASPEN chapter or section were reviewed and approved by the ASPEN Conference Program Committee.

Supported by: signifies that an organization or commercial entity outside ASPEN has provided financial resources such as an unrestricted educational grant for the session. For example: “Supported in part by Nutrition Company X” or “Supported by Nutrition Company X”.